Paolo Tarantino shared on X:
“Gene signatures have revolutionized treatment for HR+ eBC. Could they also refine treatment for more aggressive subtypes? Intriguing data of TNBC-DX from a pooled analysis of 418 patients treated with neoadjuvant taxane-based chemo.”
Source: Paolo Tarantino/X
More posts featuring Paolo Tarantino on oncodaily.com
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
